Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.

ABSTRACT:

Importance

Tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations and minimized patient-reported health status deterioration at 30 months in patients with transthyretin (ATTR) amyloidosis. However, the clinical significance of health status changes remains unclear, particularly in patients with New York Heart Association (NYHA) class III symptoms who experienced more cardiovascular-related hospitalizations than those with NYHA class I-II symptoms.

Objective

To evaluate the health status of patients taking tafamidis with baseline NYHA class III symptoms.

Design, setting, and participants

This randomized clinical trial post hoc analysis evaluated data for patients with transthyretin (ATTR) cardiac amyloidosis and NYHA class I-III symptoms at b

SUBMITTER: Sperry BW 

PROVIDER: S-EPMC9996391 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature